Although blockade of the renin–angiotensin system (RAS) is a current therapeutic approach for proteinuric CKD, including Alport syndrome, the mechanism of kidney disease progression is complex and cannot be completely ameliorated by RAS blockade only. This evidence concerns the gene REN and Alport syndrome.